Cardiovascular adverse events following treatment for non-Hodgkin lymphoma - Authors' reply

Affiliations

¹ Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht 85500, Netherlands. Electronic address: m.p.m.linschoten@umcutrecht.nl.
² Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht 85500, Netherlands.
³ Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht 85500, Netherlands; Institute of Cardiovascular Science, Faculty of Population Health Sciences, and Health Data Research UK, and Institute of Health Informatics, University College London, London, UK.

Comment

Marijke Linschoten et al. Lancet Haematol. 2020 Aug.

. 2020 Aug;7(8):e557-e558.

doi: 10.1016/S2352-3026(20)30228-3.

¹ Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht 85500, Netherlands. Electronic address: m.p.m.linschoten@umcutrecht.nl.
² Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht 85500, Netherlands.
³ Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, University of Utrecht, Utrecht 85500, Netherlands; Institute of Cardiovascular Science, Faculty of Population Health Sciences, and Health Data Research UK, and Institute of Health Informatics, University College London, London, UK.

No abstract available

Comment on

Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, Teske AJ, Asselbergs FW. Linschoten M, et al. Lancet Haematol. 2020 Apr;7(4):e295-e308. doi: 10.1016/S2352-3026(20)30031-4. Epub 2020 Mar 2. Lancet Haematol. 2020. PMID: 32135128
Cardiovascular adverse events following treatment for non-Hodgkin lymphoma.
Jayaraj R, Kumarasamy C, Raymond G, Shaw P. Jayaraj R, et al. Lancet Haematol. 2020 Aug;7(8):e557. doi: 10.1016/S2352-3026(20)30111-3. Lancet Haematol. 2020. PMID: 32735829 No abstract available.